AzTrials
AzTrials

Acute on Chronic Liver FailurePhase 4NCT02757170

Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography

A Phase 4 study testing Thromboelastography in people with Acute on Chronic Liver Failure and Cirrhosis, run by All India Institute of Medical Sciences at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Patients of acute \& chronic liver failure have long been assumed to have coagulopathy \& are given blood products prophylactically as well as during various interventions. But these patients rarely have spontaneous bleed except variceal bleed. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Acute on Chronic Liver Failure, Cirrhosis
What is being tested?
Thromboelastography
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
180 participants
Where
1 siteIndia
Study dates
Jul 2015to Jul 2016
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • All consecutive ALF, ACLF \& cirrhotic patients and healthy controls
  • Written informed consent (patient or his nearest relative)

Who cannot join

  • Patients on anti-platelet or anticoagulant therapy
  • Pregnancy and immediate post-partum period
  • History of underlying hypercoagulable/ hypocoagulable states eg. PNH, Polycythemia, Hemophilia
  • Patients with renal failure

Trial locations and contacts

1 site in 1 country.

Subrat K Acharya, DM contact

01126594425

subratacharya@gmail.com

India1 site, 1 recruiting
  • Dr. S K Acharya

    New Delhi, New Delhi, 110029

    Subrat K Acharya, DM, 01126594425, subratacharya@gmail.com

    Subrat K Acharya, DM, 9868397200, subratacharya@hotmail.com

    Recruiting

Other trials in India

About this study

Patients of acute \& chronic liver failure have long been assumed to have coagulopathy \& are given blood products prophylactically as well as during various interventions. But these patients rarely have spontaneous bleed except variceal bleed. Conventional coagulation parameters are insufficient to assess coagulation status of these patients because they reflect only a certain element of coagulation cascade while thromboelastography (TEG) gives a comprehensive report of hemostatic profile including platelet function. Studies using TEG have suggested that defects in prohemostatic drivers are counterbalanced by changes in antihemostatic drivers creating a rebalance in these patients. Acute on chronic failure is a entity with acute decompensation on underlying chronic liver failure. Since there is paucity of data regarding coagulation abnormalities in these patient, study is needed to assess predictability power of TEG in these patients with respect to coagulation abnormalities in patient with ALF and CLD ( cirrhosis) and healthy controls.

Read the detailed description

Since early times coagulopathy is considered to be an integral part of liver failure. Whether it is acute liver failure (ALF) or acute on chronic liver failure (ACLF), patients usually have deranged coagulation parameters (platelet count, prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Based on these deranged parameters, initially it was assumed that patients of liver failure have increased risk of bleeding \& usually were given blood products prophylactically during surgical interventions. But these patients of liver failure (acute or chronic) seldom develop spontaneous bleeding, apart from variceal bleeding in chronic liver failure which generally occurs because of portal hypertension. Moreover during invasive procedures also they do not have significant bleeding.

Concept of rebalanced hemostasis has been proposed to explain discrepancy between results of these coagulation parameters \& clinical scenario of patients. Normal hemostasis consists of 3 steps: platelet endothelial interaction, coagulation \& fibrinolysis. First step is considered to be defective in liver failure because of thrombocytopenia \& qualitative platelet dysfunction. However because of decreased plasma concentration of ADAMTS 13, plasma levels of vwF are increased thus increasing stickiness of platelets \& rebalancing the primary hemostasis.

Because of deranged INR, it is thought that coagulation cascade is deranged but Tripodi et al have shown that cirrhotics also can generate same amount of thrombin as healthy subjects. All procoagulants (factor II, V, VII, IX, X, XI) \& anticoagulant factors (protein C, protein S \& antithrombin) except factor VIII are synthesized in liver. Decreased procoagulant activity has been found to be counterbalanced by decreased anticoagulant proteins, thus rebalancing the whole coagulation process.

Finally, there is increased fibrinolytic activity and clot instability because of increased tissue plasminogen activator (tPA) with low levels of alpha 2 antiplasmin, factor XIII and reduced thrombin activated fibrinolysis inhibitor (TAFI). However, this is balanced by increased levels of acute phase reactant plasminogen activator inhibitor (PAI-1).

Conventional parameters like INR although can predict mortality in these cases but don't predict risk of bleeding in these patients because they monitor only a part of coagulation cascade. These parameters assess clot formation in plasma environment while in Thromboelastography (TEG) whole blood i.e. both plasma \& cellular components including platelets are assessed \& a collective report of hemostatic profile of patient is available. Graph obtained using TEG gives 5 values including r time, k time, α angle, maximum amplitude \& lysis at 30 min assessing different aspects. It has been widely used prior to cardiac surgery and liver transplant surgery to assess for coagulation defects.

In patients with stable cirrhosis, the TEG parameters are reported to lie within normal limits. TEG measurements done serially have been shown to be better than routine coagulation tests in measuring hypocoagulability in cirrhotics with early rebleeding. In decompensated cirrhotic patients, bacterial infections are common and impair hemostasis. The TEG parameters are impaired on the day of infection and recover to normal values in 5 days in cases showing response to treatment.

The results of TEG in ALF have been contrasting in the two studies which included predominantly paracetamol induced ALF. Stravitz et al in a study of 51 ALF patients reported normal TEG in 63%, 1 abnormality in 16%, 2 abnormalities in 10%, 3 abnormalities in 8% of patients and 4 abnormalities in 4% whereas 8% patients had TEG parameters in a hypercoagulable range though the mean of parameters were within normal limits in all patients. In another study of 20 ALF patients, TEG findings were consistent with a hypocoagulable state in 20%, normal in 45%, and hypercoagulable in 35% of the patients.

Acute on chronic liver failure is a recently defined entity with prolonged INR being a component of definition. The exact nature of coagulopathy in this disease has not yet been studied. In this prospective study, we propose to study the role of TEG in assessing the coagulation state in patients with ACLF and comparing the TEG parameters with respect to patients with ALF, CLD and healthy controls.

Being tested
Thromboelastography
Medical subject headings
Acute-On-Chronic Liver Failure, Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ThromboelastographyDevice

    Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.

Study groups in NCT02757170
Study groupRoleWhat they receive
IExperimentalThromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
Receives: Device: Thromboelastography
Group IIActive comparatorThromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
Receives: Device: Thromboelastography
Group IIIExperimentalThromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
Receives: Device: Thromboelastography
Group IVExperimentalThromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
Receives: Device: Thromboelastography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in r, k and MA- TEG parameters in ACLF

    Measured: 1 day

Secondary outcomes (3)
  1. Comparison of r, k and MA- TEG parameters with conventional tests of coagulation (i.e PT, aPTT)

    Measured: 1 day

  2. Development of renal failure, progression of hepatic encephalopathy, variceal bleeding and sepsis in patients with r, k and MA- TEG parameters

    Measured: 28 days

  3. Death in patients with abnormal r, k and MA- TEG parameters

    Measured: 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2016 (estimated)
  2. Study startJul 2015
  3. Primary completionJul 2016 (estimated)
  4. Study completionJul 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Screening
Allocation
Non-randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
180 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02757170
Sponsor's protocol ID
IESC/T-203/05.05.15
Status last verified
Apr 2016
First submitted
25 Apr 2016
Last updated
2 May 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Thromboelastography in people with Acute on Chronic Liver Failure and Cirrhosis, run by All India Institute of Medical Sciences at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 2 May 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Subrat K Acharya, DM (01126594425, subratacharya@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in r, k and MA- TEG parameters in ACLF (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in